Inhibitory effect of DA-125, a new anthracyclin analog antitumor agent, on the invasion of human fibrosarcoma cells by down-regulating the matrix metalloproteinases

Biochemical Pharmacology

Volumn 71, Issue 1-2, 2005, Pages 21-31

  Park, Hyen Joo ^a   Chung, Hwa Jin ^a   Min, Hye Young ^a   Park, Eun Jung ^a   Hong, Ji Young ^a   Kim, Won Bae ^b   Kim, Soon Hoe ^b   Lee, Sang Kook ^a  

^a Ewha Womans University   (South Korea)

^b Dong A Pharmaceutical Company   (South Korea)

Author keywords

Anthracyclin analog; Extracellular matrix; HT1080 cell; Invasion; Matrix metalloproteinase; NF B

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DOXORUBICIN DERIVATIVE; GALARUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; FIBROSARCOMA; GENE CONTROL; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ZYMOGRAPHY;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CELL LINE, TUMOR; DNA PRIMERS; DOWN-REGULATION; DOXORUBICIN; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FIBROSARCOMA; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; NF-KAPPA B; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC;

EID: 28244478456     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.10.007     Document Type: Article

References (70)

1. L.A. Liotta, P. Steeg, and W.G. Stetler-Stevenson Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation Cell 64 1991 327 336
2. P. Mignatti, and D.B. Rifkin Biology and biochemistry of proteinases in tumor invasion Physiol Rev 73 1993 161 195
3. M.J. Duffy The role of proteolytic enzymes in cancer invasion and metastasis Clin Exp Metastasis 10 1992 145 155
4. J. Westermarck, and V.-M. Kähäri Regulation of metalloproteinase expression in tumor invasion FASEB J 13 1999 781 792
5. L.J. McCawley, and L.M. Matrisian Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol 13 2001 534 540
6. J.F. Woessner The matrix metalloproteinase family W.C. Parks R.P. Mecham Matrix metalloproteinases 1998 Academic Press San Diego 1 14
7. P.D. Brown, R.E. Bloxidge, N.S.A. Stuart, K.C. Gatter, and J. Carmichael Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma J Natl Cancer Inst 85 1993 574 578
8. W.G. Stetler-Stevenson, L.A. Liotta, and D.E. Kleiner Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis FASEB J 7 1993 1434 1441
9. S. Zucker, R.M. Lysik, M.H. Zarrabi, and U. Moll M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer Cancer Res 5 1993 140 146
10. A.E. Yu, R.E. Hewitt, D.E. Kleiner, and W.G. Stetler-Stevenson Molecular regulation of cellular invasion-role of gelatinase A and TIMP-2 Biochem Cell Biol 74 1996 823 831
11. J. Kim, W. Yu, K. Kovalski, and L. Ossowski Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay Cell 94 1998 353 362
12. T. Itoh, M. Tanioka, H. Yoshida, T. Yoshioka, H. Nishimoto, and S. Itohara Reduced angiogenesis and tumor progression in gelatinase A-deficient mice Cancer Res 58 1998 1048 1051
13. H. Watanabe, I. Nakanishi, K. Yamashita, T. Hayakawa, and Y. Okada Matrix metalloproteinase-9 (92 kD gelatinase/type IV collagenase) from U937 monoblastoid cells: correlation with cellular invasion J Cell Sci 104 1993 991 999
14. D.E. Gomez, D.F. Alonso, H. Yoshiji, and U.P. Thorgeirsson Tissue inhibitors of metalloproteinases: structure, regulation and biological functions Eur J Cell Biol 74 1997 111 122
15. D.T. Denhardt, B. Feng, D.R. Edwards, E.T. Cocuzzi, and U.M. Malyankar Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions Pharmacol Ther 59 1993 329 341
16. H. Sato, T. Takino, Y. Okada, J. Cao, A. Shinagawa, and E. Yamamoto matrix metalloproteinase expressed on the surface of invasive tumour cells Nature 370 1994 61 65
17. G.S. Butler, M.J. Butler, S.J. Atkinson, H. Will, T. Tamura, and S.S. van Westrum The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A J Biol Chem 273 1998 871 880
18. K. Lehti, J. Lohi, H. Valtanen, and J. Keski-Oja Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface Biochem J 334 1998 345 353
19. A.Y. Strongin, I. Collier, G. Bannikov, B.L. Marmer, G.A. Grant, and G.I. Goldberg Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease J Biol Chem 270 1995 5331 5338
20. Y. Itoh, A. Ito, K. Iwata, K. Tanzawa, Y. Mori, and H. Nagase Plasma membrane-bound tissue inhibitor of metalloproteinases (TIMP)-2 specifically inhibits matrix metalloproteinase 2 (gelatinase A) activated on the cell surface J Biol Chem 273 1998 24360 24367
21. S. Zucker, M. Drews, C. Conner, H.D. Foda, Y.A. DeClerck, and K.E. Langley Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP) J Biol Chem 273 1998 1216 1222
22. Y. Jo, J. Yeon, H.J. Kim, and S.T. Lee Analysis of tissue inhibitor of metalloproteinases-2 effect on pro-matrix metalloproteinase-2 activation by membrane-type 1 matrix metalloproteinase using baculovirus/insect-cell expression system Biochem J 345 2000 511 519
23. C.M. Overall, A.E. King, D.K. Sam, A.D. Ong, T.T. Lau, and U.M. Wallon Identification of the tissue inhibitor of metalloproteinases-2 (TIMP-2) binding site on the hemopexin carboxyl domain of human gelatinase A by site-directed mutagenesis. The hierarchical role in binding TIMP-2 of the unique cationic clusters of hemopexin modules III and IV J Biol Chem 274 1999 4421 4429
24. M. Toth, M.M. Bernardo, D.C. Gervasi, P.D. Soloway, Z. Wang, and H.F. Bigg Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (membrane type 1)-MMP-dependent activation of pro-MMP-2 J Biol Chem 275 2000 41415 41423
25. L.M. Coussens, C.L. Tinkle, D. Hanahan, and Z. Werb MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis Cell 103 2000 481 490
26. B.P. Himelstein, R. Canete-Soler, E.J. Bernhard, D.W. Dilks, and R.J. Muschel Metalloproteinases in tumor progression: the contribution of MMP-9 Invasion Metastasis 14 1994 246 258
27. M. Ballin, D.E. Gomez, C.C. Sinha, and U.P. Thorgeirsson Ras oncogene mediated induction of a 92 kDa metalloproteinase; strong correlation with the malignant phenotype Biochem Biophys Res Commun 154 1988 832 838
28. J. Hua, and R.J. Muschel Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system Cancer Res 56 1996 5279 5284
29. J. Westermarck, and V.M. Kahari Regulation of matrix metalloproteinase expression in tumor invasion FASEB J 13 1999 781 792
30. A.S. Baldwin Jr. The NF-κB and IκB proteins: new discoveries and insights Annu Rev Immunol 14 1996 649 683
31. P.A. Baeuerle, and V.R. Baichwal NF-κB as a frequent target for immunosuppressive and anti-inflammatory molecules Adv Immunol 65 1997 111 137
32. S.K. Manna, N.K. Sah, R.A. Newman, A. Cisneros, and B.B. Aggarwal Oleandrin suppresses activation of nuclear transcription factor-κB, activator protein-1, and c-Jun NH2-terminal kinase Cancer Res 60 2000 3838 3847
33. W.S. Hong, H.Y. Jung, S.K. Yang, H.R. Kim, and Y.I. Min Antitumor activity of DA-125, a novel anthracycline, in human gastric and pulmonary adenocarcinoma cells resistant to adriamycin and cisplatin Anticancer Res 17 1997 3613 3616
34. Y.K. Kang, B.Y. Ryoo, T.Y. Kim, Y.H. Im, B.S. Kim, and Y.H. Park A phase II trial of DA-125, a novel anthracycline, in advanced non-small-cell lung cancer Cancer Chemother Pharmacol 44 1999 518 521
35. F. Guano, P. Pourquier, S. Tinelli, M. Binaschi, M. Bigioni, and F. Animati Topoisomerase poisoning activity of novel disaccharide anthracyclines Mol Pharmacol 56 1999 77 84
36. m loss, caspase-9 activity, and apoptosis in Jurkat cells Exp Cell Res 258 2000 223 235
37. J. Seo, H.S. Lee, M. Lee, M. Kim, and C.G. Shin DA-125, a new antitumor agent, inhibits topoisomerase II as topoisomerase poison and DNA intercalator simultaneously Arch Pharm Res 27 2004 77 82
38. S.G. Kim, M. Sung, K.W. Kang, S.H. Kim, M.H. Son, and W.B. Kim DA-125, a novel anthracycline derivative showing high-affinity DNA binding and topoisomerase II inhibitory activities, exerts cytotoxicity via c-Jun N-terminal kinase pathway Cancer Chemother Pharmacol 47 2001 511 518
39. A. Ballester, A. Velasco, R. Tobena, and S. Alemany Cot kinase activates tumor necrosis factor-α gene expression in a cyclosporin A-resistant manner J Biol Chem 273 1998 14099 14106
40. A.A. Beg, T.S. Finco, P.V. Nanterment, and A.S. Baldwin Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of IκBα: a mechanism for NF-κB activation Mol Cell Biol 13 1993 3301 3310
41. M.M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal Biochem 72 1976 248 254
42. A. Di Marco, M. Gaetani, and B. Scarpinato Adriamycin (NSC-123,127): a new antibiotic with antitumor activity Cancer Chemother Rep 53 1969 33 37
43. R.H. Blum, and S.K. Carter Adriamycin. A new anticancer drug with significant clinical activity Ann Intern Med 80 1974 249 259
44. E.A. Lefrak, J. Pitha, S. Rosenheim, and J.A. Gottlieb A clinicopathologic analysis of adriamycin cardiotoxicity Cancer 32 1973 302 314
45. S.K. Carter Adriamycin - a review J Natl Cancer Inst 55 1975 1265 1274
46. J.C. Kim, K.H. Kim, and M.K. Chung Testicular cytotoxicity of DA-125, a new anthracycline anticancer agent, in rats Reprod Toxicol 13 1999 391 397
47. L.A. Liotta, K. Tryggvason, S. Garbisa, I. Hart, C.M. Foltz, and S. Shafie Metastatic potential correlates with enzymatic degradation of basement membrane collagen Nature 284 1980 67 68
48. F.J. Bianco Jr., D.C. Gervasi, R. Tiguert, D.J. Grignon, J.E. Pontes, and J.D. Crissman Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade Clin Cancer Res 4 1998 3011 3016
49. H. Birkedal-Hansen, W.G. Moore, M.K. Bodden, L.J. Windsor, B. Birkedal-Hansen, and A. DeCarlo Matrix metalloproteinases: a review Crit Rev Oral Biol Med 4 1993 197 250
50. H. Sato, and M. Seiki Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells Oncogene 8 1993 395 405
51. M.I. Cockett, G. Murphy, M.L. Birch, J.P. O'Connell, T. Crabbe, and A.T. Millican Matrix metalloproteinases and metastatic cancer Biochem Soc Symp 63 1998 295 313
52. A.S. Papathoma, V. Zoumpourlis, A. Balmain, and A. Pintzas Role of matrix metalloproteinase-9 in progression of mouse skin carcinogenesis Mol Carcinog 31 2001 74 82
53. T. Itoh, M. Tanioka, H. Matsuda, H. Nishimoto, T. Yoshioka, and R. Suzuki Experimental metastasis is suppressed in MMP-9-deficient mice Clin Exp Metastasis 17 1999 177 181
54. A.H. Drummond, P. Beckett, P.D. Brown, E.A. Bone, A.H. Davidson, and W.A. Galloway Preclinical and clinical studies of MMP inhibitors in cancer Ann N Y Acad Sci 878 1999 228 235
55. W.G. Stetler-Stevenson, P.D. Brown, M. Onisto, A.T. Levy, and L.A. Liotta Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues J Biol Chem 265 1990 13933 13938
56. Y.A. De Clerck, M.I. Darville, Y. Eeckhout, and G.G. Rousseau Characterization of the promoter of the gene encoding human tissue inhibitor of metalloproteinases-2 (TIMP-2) Gene 139 1994 185 191
57. Z.M. Shao, J. Wu, Z.Z. Shen, and S.H. Barsky Genistein exerts multiple suppressive effects on human breast carcinoma cells Cancer Res 58 1998 4851 4857
58. H.J. Cha, S.K. Bae, H.Y. Lee, O.H. Lee, H. Sato, and M. Seiki Anti-invasive activity of ursolic acid correlates with the reduced expression of matrix metalloproteinase-9 (MMP-9) in HT1080 human fibrosarcoma cells Cancer Res 56 1996 2281 2284
59. 3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells Cell Growth Differ 11 2000 221 229
60. S.C. Chu, H.L. Chiou, P.N. Chen, S.F. Yang, and Y.S. Hsieh Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2 Mol Carcinog 40 2004 143 149
61. V. Bours, G. Bonizzi, M. Bentires-Alj, F. Bureau, J. Piette, and P. Lekeux NF-κB activation in response to toxical and therapeutical agents: role in inflammation and cancer treatment Toxicology 153 2000 27 38
62. M. Wu, H. Lee, R.E. Bellas, S.L. Schauer, M. Arsura, and D. Katz Inhibition of NF-κB/Rel induces apoptosis of murine B cells EMBO J 15 1996 4682 4690
63. Y. Yamamoto, and R.B. Gaynor Role of the NF-κB pathway in the pathogenesis of human disease states Curr Mol Med 1 2001 287 296
64. M. Bond, R.P. Fabunmi, A.H. Baker, and A.C. Newby Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-κB FEBS Lett 435 1998 29 34
65. A.R. Farina, A. Tacconelli, A. Vacca, M. Maroder, A. Gulino, and A.R. Mackay Transcriptional up-regulation of matrix metalloproteinase-9 expression during spontaneous epithelial to neuroblast phenotype conversion by SK-N-SH neuroblastoma cells, involved in enhanced invasivity, depends upon GT-box and nuclear factor κB elements Cell Growth Differ 10 1999 353 367
66. S.O. Yoon, M.M. Kim, and A.S. Chung Inhibitory effect of selenite on invasion of HT1080 tumor cells J Biol Chem 276 2001 20085 20092
67. I.Y. Kim, and T.C. Stadtman Inhibition of NF-κB DNA binding and nitric oxide induction in human T cells and lung adenocarcinoma cells by selenite treatment Proc Natl Acad Sci USA 94 1997 12904 12907
68. W.C. Ho, K.M. Dickson, and P.A. Barker Nuclear factor-kappaB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-κB-dependent transcription in cancer cells Cancer Res 65 2005 4273 4281
69. C. Weber, W. Erl, A. Pietsch, M. Strobel, H.W. Ziegler-Heitbrock, and P.C. Weber Antioxidants inhibit monocyte adhesion by suppressing nuclear factor-κB mobilization and induction of vascular cell adhesion molecule-1 in endothelial cells stimulated to generate radicals Arterioscler Thromb 14 1994 1665 1673
70. S. Shishodia, P. Potdar, C.G. Gairola, and B.B. Aggarwal Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-κB activation through inhibition of IκBα kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1 Carcinogenesis 24 2003 1269 1279